Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients

Adjuvant chemotherapy for breast cancer patients has been derived from the results of various clinical studies and metaanalysis. Currently, an anthracycline-containing regimen is a standard chemotherapy for node-negative breast cancer patients with any risk of recurrence. Node-positive breast cancer patients employ AC followed by taxane. The concept of dose-dense therapy or adjuvant trastuzumab for HER 2-positive breast cancer patients will be introduced in the near future. We have to catch the procedures of standard treatments and treat our patients with the latest knowledge. Therefore, we can refer to any guidelines based on evidence-based medicine.